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Microglia are macrophage-like resident immune cells that contribute to the maintenance
of homeostasis in the central nervous system (CNS). Abnormal activation of microglia
can cause damage in the CNS, and accumulation of activated microglia is a characteristic
pathological observation in neurologic conditions such as trauma, stroke, inflammation,
epilepsy, and neurodegenerative diseases. Activated microglia secrete high levels of
glutamate, which damages CNS cells and has been implicated as a major cause
of neurodegeneration in these conditions. Glutamate-receptor blockers and microglia
inhibitors (e.g., minocycline) have been examined as therapeutic candidates for several
neurodegenerative diseases; however, these compounds exerted little therapeutic benefit
because they either perturbed physiological glutamate signals or suppressed the actions
of protective microglia. The ideal therapeutic approach would hamper the deleterious roles
of activated microglia without diminishing their protective effects. We recently found that
abnormally activated microglia secrete glutamate via gap-junction hemichannels on the
cell surface. Moreover, administration of gap-junction inhibitors significantly suppressed
excessive microglial glutamate release and improved disease symptoms in animal models
of neurologic conditions such as stroke, multiple sclerosis, amyotrophic lateral sclerosis,
and Alzheimer’s disease. Recent evidence also suggests that neuronal and glial
communication via gap junctions amplifies neuroinflammation and neurodegeneration.
Elucidation of the precise pathologic roles of gap junctions and hemichannels may lead to
a novel therapeutic strategies that can slow and halt the progression of neurodegenerative
diseases.
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INTRODUCTION
Microglia are macrophage-like immune cells that reside in the
central nervous system (CNS), where they play multiple roles:
presenting antigen to initiate immunological reactions, direct-
ing attack against non-self antigens, debris clearance, support of
neuronal circuit development (Kreutzberg, 1996; Kempermann
and Neumann, 2003; Block et al., 2007; Takeuchi, 2010; Boche
et al., 2013), and so on. Microglia contribute to maintenance of
CNS homeostasis, but abnormal activation of these cells often
causes damage to surrounding cells and tissues. Microgliosis, the
accumulation of activated microglia, is a characteristic patho-
logical feature in many neurologic conditions such as trauma,
stroke, inflammation, epilepsy, and neurodegenerative diseases
(Cagnin et al., 2001; Eikelenboom et al., 2002; McGeer and
McGeer, 2002; Nelson et al., 2002; Orr et al., 2002; Bruijn
et al., 2004; Pavese et al., 2006). Activated microglia release
massive amounts of glutamate, at much higher levels than astro-
cytes and neurons (mM vs. μM), and destroy neural cells;
these processes have been implicated as a major cause of neu-
ronal damage in neurologic diseases (Piani et al., 1992; Barger
and Basile, 2001; Schwartz et al., 2003; Ye et al., 2003; Kipnis
et al., 2004; Takeuchi et al., 2005, 2008b; Herman and Jahr,
2007; Liang et al., 2008; Yawata et al., 2008). Therefore, block-
ade of glutamate signaling and inhibition of microglial acti-
vation have been explored as therapeutic candidates for sev-
eral neurodegenerative diseases. However, glutamate receptor
blockers also perturb physiological glutamate signals and cause
severe adverse side effects (Parsons et al., 2007). Tetracycline
and two of its derivatives (doxycycline and minocycline) have
been used as inhibitors of microglial activation, but these
compounds exerted little therapeutic benefit, because activated
microglia also exert neuroprotective effects such as production
of neurotrophic factors and sequestration of neurotoxic sub-
stances (Zietlow et al., 1999; Kempermann and Neumann, 2003;
Kipnis et al., 2004; Koenigsknecht and Landreth, 2004; Schwab
and Schluesener, 2004). Thus, the optimal therapeutic strat-
egy would inhibit the deleterious effects of activated microglia
without diminishing their protective roles (Takeuchi, 2010). We
recently found that neurotoxic activated microglia secrete glu-
tamate through gap-junction hemichannels. Recent evidence
also suggests that neuronal and glial communication by gap
junctions amplifies neuroinflammation and neurodegeneration.
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Therefore, elucidation of the pathologic roles of gap junctions
and hemichannels may provide us with new therapeutic strategies
against many neurologic diseases.
MICROGLIA AS THE “ENEMYWITHIN”
Microglia, which originate from bone marrow–derived myeloid
cells, account for approximately 10% of cells in the human CNS
(Del Rio-Hortega, 1932). Microglia are predominantly observed
in gray matter, especially in the olfactory bulb, hippocampus,
basal ganglia, and substantia nigra (Lawson et al., 1990). Under
healthy physiological conditions, microglia persist in a quiescent
state with ramified morphology (resting microglia) and survey
the environment of the CNS (Davalos et al., 2005; Nimmerjahn
et al., 2005). Under pathological conditions, microglia dramati-
cally change their morphology and adopt an amoeboid appear-
ance in the activated state. Activated microglia express surface
molecules such as Fc receptor, CD11b, CD11c, CD14, major his-
tocompatibility complex (MHC) molecules, Toll-like receptors
(TLRs), scavenger receptors, and cytokine/chemokine receptors,
and they can act as both antigen-presenting cells and immuno-
logical effector cells (Suzumura et al., 1987; Rock et al., 2004). In
addition to innate immunity, activated microglia also play other
beneficial roles, such as neuroprotection mediated by release of
neurotrophic factors (Zietlow et al., 1999; Bessis et al., 2007; Liang
et al., 2010), maintenance of CNS homeostasis by clearance of
cellular debris and toxic substances (Upender and Naegele, 1999;
Marin-Teva et al., 2004; Iribarren et al., 2005; Simard et al., 2006;
Richard et al., 2008), and guidance of stem-cell migration in neu-
ronal repair and neurogenesis (Aarum et al., 2003; Ziv et al.,
2006a,b).
TLRs and scavenger receptors may contribute to diminishing
neurotoxicity by sequestering neurotoxic substances such as amy-
loid β (El Khoury et al., 1996; Coraci et al., 2002; Bamberger
et al., 2003; Liu et al., 2005); however, signals downstream of
these receptors also enhance microglial neurotoxic effects by pro-
ducing neurotoxic factors such as cytokines/chemokines, nucleic
acids, excitatory amino acids, reactive oxygen species (ROS), and
proteases (Kempermann and Neumann, 2003; Takeuchi et al.,
2005, 2006; Kawanokuchi et al., 2006; Block et al., 2007). In fact,
expression levels of TLRs and scavenger receptors are upregulated
in a variety of neurologic diseases (Akiyama and McGeer, 1990;
Grewal et al., 1997; El Khoury et al., 1998; Bsibsi et al., 2002;
Cho et al., 2005; Carpentier et al., 2008). Therefore, whether acti-
vated microglia exert a neurotoxic or a neuroprotective effect may
depend on their environment, the spatiotemporal distribution of
the microglia themselves, and the type and magnitude of stimuli
(Jimenez et al., 2008; Wu et al., 2008; Nakanishi and Wu, 2009;
Sawada, 2009). A recently proposed hypothesis suggests, by anal-
ogy to macrophage activation, that activated microglia comprise
two subpopulations, the neurotoxic (M1) and neuroprotective
(M2) species (Mantovani et al., 2002; Henkel et al., 2009; Boche
et al., 2013); however, this hypothesis is still open to debate. At
least in pathological conditions, deleterious microglial activation
is probably involved in the progression of various neurological
disorders (Yrjanheikki et al., 1998; Wu et al., 2002; Zhu et al.,
2002; Stirling et al., 2004; Boillee et al., 2006; Seabrook et al.,
2006). Thus, elucidating the precise mechanism of microglial
neurotoxicity is a necessary step toward development of effective
therapeutic strategies against neurologic diseases.
GLUTAMATE AS A MAJOR NEUROTOXIC FACTOR FROM
MICROGLIA
Glutamate is the most potently neurotoxic factor released from
activated microglia. Excessive glutamate induces severe neuronal
damage via excitotoxicity (Piani et al., 1992; Barger and Basile,
2001; Takeuchi et al., 2005, 2006). A common misconception
is that inflammatory cytokines produced by activated microglia
directly induce neuronal damage. In fact, these cytokines have lit-
tle direct neurotoxic effect (Takeuchi et al., 2006; Takeuchi, 2010).
Although tumor necrosis factor-α (TNF-α) and interferon-γ
(IFN-γ) are considered to be the most deleterious inflammatory
cytokines produced by activated microglia, these cytokines have
only weak direct neurotoxic effects because they also enhance
neuroprotective cascades involving mitogen-activated protein
kinase (MAPK) and expression of nuclear factor κB (NF-κB)
(Ghezzi and Mennini, 2001; Kamata et al., 2005). In general,
inflammatory cytokines induce neurotoxicity indirectly by stimu-
lating microglia in an autocrine/paracrine manner. These stimuli
induce microglia to release high levels of glutamate, resulting
in neuronal damage via excitotoxicity. Moreover, a recent paper
showed that activated microglial glutamate suppresses astrocytic
glutamate transporters, which play a pivotal role in maintenance
of the physiological extracellular glutamate level (Takaki et al.,
2012); this suppression probably worsens excitotoxic neuronal
damage. Although microglia also express glutamate transporters,
they seem much less effective at maintaining extracellular gluta-
mate homeostasis than astrocytic glutamate transporters (Liang
et al., 2008).
One of the earliest pathologic features of excitotoxicity is
formation of neuritic beading, i.e., focal bead-like swelling in
dendrites and axons (Takeuchi et al., 2005; Mizuno et al.,
2008). Neuritic beading is a common neuropathological hall-
mark of many neurologic conditions such as ischemia, epilepsy,
mechanical pressure, brain tumor, aging, neuroinflammatory
diseases, and neurodegenerative diseases such as multiple scle-
rosis (MS), Alzheimer’s disease (AD), Parkinson’s disease (PD),
and amyotrophic lateral sclerosis (ALS) (Delisle and Carpenter,
1984; Hori and Carpenter, 1994; Takahashi et al., 1997; Trapp
et al., 1998; Dickson et al., 1999; Mattila et al., 1999; Swann
et al., 2000; Goel et al., 2003; Pavlidis et al., 2003; Saito et al.,
2003; Dutta and Trapp, 2007). Recent studies elucidated the
detailed role of microglial glutamate in formation of neuritic
beading and subsequent neuronal death. Glutamate produced
by activated microglia activates neuronal N-methyl-D-aspartate
(NMDA) receptor signaling, which promotes Ca2+ influx and
activates Ca2+/calmodulin-dependent protein kinase (CaMK).
CaMK activates neuronal nitric oxide synthase (nNOS) and
increases the intracellular concentration of nitric oxide (NO).
NO in turn inhibits mitochondrial respiratory chain complex
IV, resulting in a rapid reduction in intracellular ATP levels.
Ultimately, the loss of intracellular energy pools suppresses den-
dritic and axonal transport, leading to bead-like accumulation of
cytoskeletal and motor proteins along neurites and the formation
of neuritic beading. Thus, a low-energy state results in neuronal
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dysfunction. Persistence of this neuronal dysfunction eventu-
ally causes neuronal death [i.e., excitotoxic neuronal death or
non-cell-autonomous neuronal death (Lobsiger and Cleveland,
2007)].
Recent studies have revealed the precise mechanism of gluta-
mate production by activated microglia (Takeuchi et al., 2005,
2006) (Figure 1). Two pathways are involved in cellular gluta-
mate synthesis (Newsholme and Newsholme, 1989; Newsholme
and Calder, 1997; Yudkoff, 1997; Nissim, 1999). One of these
pathways is mediated by glutamate dehydrogenase, which con-
verts α-ketoglutarate to glutamate. Most cells use this pathway
to maintain cellular homeostasis of glutamate levels. The other
pathway is mediated by glutaminase, which produces glutamate
from extracellular glutamine brought into the cell via glutamine
transporters. Resting microglia maintain their physiological glu-
tamate level via the glutamate dehydrogenase pathway, as in other
cell types, and secrete very little glutamate into the extracellu-
lar space (Figure 1). By contrast, activated microglia produce
excessive amounts of glutamate as a result of upregulation of
glutaminase, but not glutamate dehydrogenase. Subsequently,
activated microglia release massive amounts of glutamate via gap-
junction hemichannels. Inflammatory cytokines such as TNF-α
and IFN-γ enhance not only glutaminase expression level but also
cell-surface localization of hemichannels in microglia (Eugenin
et al., 2001; Takeuchi et al., 2006). These two phenomena may
act synergistically to release excess glutamate, leading to exci-
totoxic neuronal damage (Figure 1). Moreover, the extracellular
glutamine level is critical for microglial glutamate production
(Takeuchi et al., 2006). In the CNS, glutamine from astrocytes is
essential for glutamate production in neurons (Tsacopoulos and
Magistretti, 1996), suggesting that it also plays an important role
in microglial glutamate production.
GAP JUNCTIONS IN CNS CELLS
Gap junctions contribute to formation of intercellular channels
that directly connect the cytoplasmic compartments of neighbor-
ing cells (Yeager and Harris, 2007). These channels pass various
small molecules (∼1000Da) and ions, although the charges and
shapes of these molecules may affect the rate of transfer through
gap junctions (Goldberg et al., 2004). Each gap junction is com-
posed of a pair of hemichannels docked in a head-to-head config-
uration. Hemichannels are organized as hexagonal cylinders with
central pores, and each hemichannel consists of a hexameric clus-
ter of protein subunits called connexins (in vertebrates) or innex-
ins (in invertebrates). Connexins are encoded by a conserved
family of genes with at least 21 members in mammals. There
are 21 connexin genes in the human genome and 20 connexin
genes in the mouse genome; 19 of these proteins have orthologs
in both humans and mice (Willecke et al., 2002; Laird, 2006).
The connexin isoforms structurally interact in multiple ways.
Homomeric hemichannels consist of a single connexin isoform,
whereas heteromeric hemichannels contain two or more different
connexin isoforms. Likewise, a homotypic gap junction channel
is composed of two identical hemichannels, whereas a heterotypic
gap junction channel contains two different hemichannels. Thus,
the compositions of gap junctions can be classified into four
types: homomeric and homotypic; heteromeric and homotypic;
homomeric and heterotypic; and heteromeric and heterotypic
FIGURE 1 | Mechanism of glutamate production and release by
activated microglia. Like other types of cells, resting microglia use
glutamate dehydrogenase to synthesize glutamate from intracellular
α-ketoglutarate in order to maintain a physiologically normal level of
glutamate. Under resting conditions, microglia release very little glutamate
into the extracellular space. By contrast, under pathological conditions,
glutaminase and gap-junction hemichannels are upregulated in activated
microglia (e.g., in response to stimulation by TNF-α). Glutaminase
synthesizes excess glutamate from extracellular glutamine, which is
brought into the cell via glutamine transporters. Subsequently, high levels
of glutamate are secreted through gap-junction hemichannels, resulting in
eventual neuronal damage.
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FIGURE 2 | The composition of gap junctions and hemichannels. Each
colored column (orange, blue, green, or purple) represents a different
connexin isoform. Hemichannels may be homomeric (composed of one
connexin isoform) or heteromeric (composed of more than one connexin
isoform). Gap-junction channels may be homotypic (formed by identical
hemichannels) or heterotypic (formed by different hemichannels).
(Figure 2). This heterogeneity of connexin configurations confers
complexity to the gap junction/hemichannel system.
Gap junctions allow direct intracellular propagation of sec-
ond messengers (e.g., Ca2+, IP3, cAMP, and cGMP), metabolites
(e.g., glutamate, glucose, and glutathione), and nucleotides (e.g.,
ATP, ADP, and RNA) between adjacent cells (Goldberg et al.,
1999, 2002; Harris, 2001, 2007; Saez et al., 2003; Valiunas et al.,
2005; Laird, 2006). Moreover, recent studies revealed that uncou-
pled “free” hemichannels facilitate two-way transfer of molecules
between the cytosol and extracellular milieu (De Vuyst et al.,
2007; Retamal et al., 2007; Laird, 2010). Intracellular commu-
nication via gap junctions and hemichannels is regulated by
such mechanisms as channel gating via chemicals, pH, and
voltage, as well as by changes in connexin transcription, trans-
lation, post-translational phosphorylation and ubiquitination,
membrane insertion, and hemichannel internalization and degra-
dation (Laird, 2006; Leithe and Rivedal, 2007; Solan and Lampe,
2009). The time courses of these changes range frommilliseconds
to hours and are influenced by the environmental conditions in
cells and tissues.
Whereas vertebrate cells use connexins to form gap junctions
and hemichannels, invertebrate cells use innexins, which lack
sequence homology to connexins. A search of the human genome
identified three innexin-related genes (Barbe et al., 2006). Because
of the occurrence of homologous genes in both vertebrates
and invertebrates, the corresponding proteins were termed pan-
nexins: pannexin1 (Panx1), pannexin2 (Panx2), and pannexin3
(Panx3). Pannexins have the same transmembrane topology as
connexins, with four transmembrane domains and cytoplasmic
amino-terminal and carboxyl-terminal domains. Recent evidence
indicates that pannexins also form uncoupled hemichannels in
mammalian cells; however, it is not clear whether they can form
functional gap junctions (Dahl and Locovei, 2006).
Tissues have characteristic connexin expression profiles, and
neural cells in the CNS express multiple connexins (Dermietzel
et al., 1989, 2000; Bittman and Loturco, 1999; Chang et al.,
1999; Nagy and Rash, 2000; Eugenin et al., 2001; Rash et al.,
2001; Teubner et al., 2001; Altevogt et al., 2002; Parenti
et al., 2002; Rouach et al., 2002; Odermatt et al., 2003;
Takeuchi et al., 2006). All neurons express Cx36 and Cx45,
whereas other neural connexins are expressed with more specific
spatiotemporal profiles (Sohl et al., 2005). Electrical coupling
between neurons has been implicated in neuronal synchroniza-
tion in the CNS (Christie et al., 1989; Bouskila and Dudek, 1993;
Wong et al., 1995). Neuronal gap junctions composed of Cx36
and Cx45 are thought to be homomeric and homotypic (Al-
Ubaidi et al., 2000; Teubner et al., 2001), and these junctions are
important for formation of electrical synapses (Deans et al., 2001;
Hormuzdi et al., 2001). Rodent knockout models have shown that
other connexins can compensate for the functions of Cx36 and
Cx45, despite differences in conformation or permeability (Frank
et al., 2010; Zlomuzica et al., 2010). Furthermore, there is accu-
mulating evidence that gap-junction coupling plays a pivotal role
in neuronal differentiation. Mice lacking Cx43 exhibit neonatal
death and abnormal migration in the neural crest and neocortex
(Lo et al., 1999; Xu et al., 2001; Fushiki et al., 2003). Blockade of
gap junctions also hampers retinoic acid–induced neuronal dif-
ferentiation of NT2 and P19 cells (Bani-Yaghoub et al., 1999a,b).
Moreover, Cx36-containing gap junctions are important in neu-
ronal remodeling and short-term spatial memory in somemature
organisms (Allen et al., 2011; Hartfield et al., 2011). In contrast to
neuron–neuron coupling, for which the evidence is convincing,
the existence of functional neuron–glia coupling in the CNS is
still a matter of debate (Nadarajah et al., 1996; Alvarez-Maubecin
et al., 2000; Rash et al., 2001, 2007).
Astrocytes, the main CNS cells coupled via gap junctions, pri-
marily express Cx43 and Cx30 (Dermietzel et al., 1991; Nagy and
Rash, 2000). Consistent with this, Cx43/Cx30 double-knockout
mice exhibit minimal gap-junction communication between
astrocytes (Wallraff et al., 2006; Rouach et al., 2008), suggesting
that functional astrocytic gap junctions are composed predomi-
nantly of these two connexins. Cx43-deficient astrocytes exhibit
reduced gap-junction coupling, although they express other con-
nexin subtypes including Cx30, Cx26, Cx40, Cx45, and Cx46
(Naus et al., 1997; Scemes et al., 1998; Dermietzel et al., 2000).
Although Cx30 has been detected exclusively in astrocytes, Cx30
knockout mice develop only mild abnormalities, including hear-
ing loss due to cochlear degeneration (Teubner et al., 2003).
Thus, other astrocytic connexin subtypes do not seem to com-
pensate for a lack of Cx43. Astrocytic gap junctions facilitate
the formation of functional syncytium that buffers extracellu-
lar glutamate elevation, pH, and K+ concentrations associated
with firing neurons, and also propagates intracellular Ca2+ waves
that modulate neuronal activities (Walz and Hertz, 1983; Jefferys,
1995; Charles, 1998; Anderson and Swanson, 2000; Ransom et al.,
2003). Moreover, astrocytic gap-junction communication facili-
tates trafficking of glucose and its metabolites, thereby mediating
interactions between cerebral vascular endothelium and neurons
(Giaume et al., 1997; Goldberg et al., 1999; Tabernero et al., 2006).
Thus, astrocytic gap junctions play pivotal roles in modulating
neuronal activities andmaintaining CNS homeostasis. Astrocyte–
astrocyte coupling can be achieved by any of the allowed
combinations of homomeric or heteromeric hemichannels in
homotypic or heterotypic configurations. Cx30 and Cx26 form
both heteromeric and heterotypic channels (Nagy et al., 2003;
Altevogt and Paul, 2004), whereas Cx43 forms homomeric and
homotypic channels (Orthmann-Murphy et al., 2007). A previ-
ous report demonstrated that gap-junction coupling in astrocytes
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results in two distinct subpopulations of cells. Astrocytes express-
ing glutamate transporters are extensively coupled to each other,
whereas strocytes expressing glutamate receptors are not coupled
to other astrocytes (Wallraff et al., 2004), suggesting that these
cells play a role in buffering extracellular glutamate (Anderson
and Swanson, 2000).
Oligodendrocytes primarily express Cx29, Cx32, and Cx47
(Dermietzel et al., 1989; Altevogt et al., 2002; Odermatt et al.,
2003). Oligodendrocytic gap junctions facilitate the trafficking of
ions and nutrients from somas to myelin layers (Paul, 1995). Mice
lacking Cx32 exhibit reduced myelin volume, enhanced excitabil-
ity in the CNS, and progressive peripheral neuropathies (Anzini
et al., 1997; Sutor et al., 2000). Cx32/Cx47 double-knockout mice
develop abnormal movements and seizures associated with vac-
uolated myelin and axonal degeneration in the CNS, whereas
Cx47-deficient mice exhibit only minimal CNS abnormalities
(Menichella et al., 2003). Cx32 and Cx47 in oligodendrocytes
are essential for spatial buffering of K+ in response to neu-
ronal activity; failure of this function leads to myelin swelling
and subsequent axonal degeneration (Menichella et al., 2006).
Oligodendrocyte–oligodendrocyte coupling is mediated by gap
junctions in homotypic configurations with homomeric or het-
eromeric hemichannels containing Cx32 or Cx47 (Orthmann-
Murphy et al., 2007). Furthermore, oligodendrocytes also couple
with astrocytes. Astrocyte–oligodendrocyte coupling may include
heterotypic configurations of Cx43–Cx47, Cx30–Cx32, or Cx26–
Cx32 (Nagy et al., 2003; Altevogt and Paul, 2004; Orthmann-
Murphy et al., 2007). In addition to astrocyte–astrocyte coupling,
astrocyte–oligodendrocyte coupling is important in the glial syn-
cytium to facilitate the propagation of Ca2+ waves and the buffer-
ing of extracellular K+ and neurotransmitters such as glutamate
(Walz and Hertz, 1983; Jefferys, 1995; Charles, 1998; Anderson
and Swanson, 2000; Ransom et al., 2003).
Microglia express Cx32, Cx36, and Cx43 (Eugenin et al., 2001;
Parenti et al., 2002; Garg et al., 2005; Takeuchi et al., 2006;
Kielian, 2008; Talaveron et al., 2014), but form few functional gap
junctions under resting conditions. The expression of connexins
rises in activated microglia, although it remains unclear whether
upregulated expression of connexins leads to enhanced formation
of functional gap junctions with microglia and other CNS cells
(Eugenin et al., 2001; Garg et al., 2005; Kielian, 2008; Takeuchi,
2010; Wasseff and Scherer, 2014). Recent evidence demonstrates
that uncoupled microglial hemichannels play important roles in
bidirectional trafficking of small molecules between the cyto-
plasm and extracellular space (Takeuchi et al., 2011; Eugenin et al.,
2012).
The evidence described above might give the false impression
that CNS cells express only a narrow range of combinations of
homomeric hemichannels and gap junctions. However, the pre-
cise configuration of these hemichannels [i.e., homomeric and
homotypic; heteromeric and homotypic; homomeric and het-
erotypic; and heteromeric and heterotypic (Figure 2)] has yet
to be elucidated. In addition, our recent reverse transcription–
PCR analysis using mouse primary cultures indicated that gap
junctions/hemichannels in neurons and glial cells may consist
of a wider range of combinations of connexins than expected
(Table 1) (Takeuchi et al., 2014): neurons predominantly express
Table 1 | mRNA expression levels of mouse connexin in CNS cells.
Mouse mRNA expression level
Protein Gene Neuron Microglia Astrocyte Oligodendrocyte
Cx43 Gja1 ++ ± + + + +
Cx46 Gja3 + + + + + ++
Cx37 Gja4 + + + + ++ + + +
Cx40 Gja5 + + + + + + + +
Cx33 Gja6 + ++ + ++
Cx50 Gja8 + + + + ± +
Cx57 Gja10 ± + + + + + + + + +
Cx32 Gjb1 + + + + + + + +
Cx26 Gjb2 + + + + + + + +
Cx31 Gjb3 ++ ++ ++ ++
Cx30.3 Gjb4 ++ ++ ++ ++
Cx31.1 Gjb5 + + + + + +
Cx30 Gjb6 ± + + + + +
Cx45 Gjc1 − + + + + ±
Cx47 Gjc2 ± + + + + +
Cx29 Gjc3 ++ + ± ++
Cx36 Gjd2 + + + ++ − ++
Cx30.2 Gjd3 + ++ ++ + + +
Cx39 Gjd4 ± ++ ++ + + +
Cx23 Gje1 ± ++ ++ + + +
−, none; ±, slight; +, low; ++, moderate; + + +, high.
Cx43, Cx50, Cx31, Cx30.3, Cx29, and Cx36; microglia predom-
inantly express Cx46, Cx37, Cx40, Cx33, Cx57, Cx32, Cx31,
Cx30.3, Cx47, Cx36, Cx30.2, Cx39, and Cx23; astrocytes pre-
dominantly express Cx43, Cx37, Cx57, Cx26, Cx31, Cx30.3,
Cx45, Cx30.2, Cx39, and Cx23; and oligodendrocytes predomi-
nantly express Cx46, Cx37, Cx40, Cx33, Cx57, Cx32, Cx26, Cx31,
Cx30.3, Cx31.1, Cx30, Cx29, Cx36, Cx30.2, Cx39, and Cx23.
These findings imply that connexin expression profiles in the CNS
are dynamic, both in healthy and pathological states.
GAP JUNCTIONS COMPOSED OF CONNEXINS AS A NOVEL
THERAPEUTIC TARGET FOR NEUROLOGIC DISEASES
As mentioned above, glial gap junctions play an important role
in maintenance of homeostasis in the CNS under the physio-
logical conditions. These structures, however, also contribute to
the initiation and propagation of pathologic conditions (Orellana
et al., 2009). Stroke and trauma provide examples that illus-
trate this mechanism. Ischemia or contusion leads to a rapid
decrease in intracellular oxygen levels and subsequent reduc-
tion in ATP synthesis, resulting in eventual cell death (Kalogeris
et al., 2012). Injured cells contain toxic ions and molecules at
high concentrations (e.g., Ca2+, K+, ROS, and NO). These toxic
molecules are propagated from injured cells to healthier cells
through gap junctions. Ischemic conditions also induce uncou-
pled hemichannels to open, leading to paracrine transfer of toxic
molecules (Thompson et al., 2006; De Vuyst et al., 2007). These
waves of death signals activate astrocytes and microglia, induc-
ing the release of toxic molecules including glutamate, ROS, NO,
and pro-inflammatory cytokines and chemokines. This vicious
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amplification spiral of signaling could worsen neuroinflamma-
tion by recruiting leukocytes and increasing the lesion area
(Orellana et al., 2009) (Figure 3). Moreover, gap junction and
hemichannel blockers have exerted therapeutic effects in exper-
imental models of stroke and spinal cord injury (Rawanduzy
et al., 1997; Frantseva et al., 2002; De Pina-Benabou et al., 2005;
Takeuchi et al., 2008a; Tamura et al., 2011; Huang et al., 2012;
Umebayashi et al., 2014).
Abnormal expression of glial connexins has been observed in
the inflamed lesions in multiple sclerosis (MS) and an animal
model of this disease, experimental autoimmune encephalomyeli-
tis (EAE). In particular, downregulation of oligodendrocytic
Cx32 and Cx47 and astrocytic Cx43 have been observed in the
active lesions of MS patients and EAE mice (Brand-Schieber
et al., 2005; Eugenin et al., 2012; Markoullis et al., 2012).
Expression levels of Cx47 and Cx32 were upregulated during
remyelination, but downregulated in the relapsing phase, and
Cx32 deletion resulted in exacerbates symptoms in EAE, specif-
ically increased demyelination and axonal loss (Markoullis et al.,
2012). Whereas mice lacking astrocytic expression of Cx43/Cx30
exhibited white-matter vacuolation and hypomyelination, the
severity of EAE in these animals was similar to that in wild-type
mice (Lutz et al., 2012). Therefore, oligodendrocytic expression
levels of Cx32 and Cx47 appear to be associated with the degree
of damage and remyelination, whereas astrocytic expression lev-
els of Cx43 do not. However, recent studies showed that a loss of
Cx43 in astrocytes precedes demyelination in the MS-related dis-
orders neuromyelitis optica and Balo’s disease (Matsushita et al.,
2011; Masaki et al., 2012), suggesting that the temporal expres-
sional pattern of astrocytic Cx43 plays a significant role in the
disease process.
Accumulating evidence has also implicated neuroinflamma-
tion, including gliosis by activated astrocytes and microglia,
in the pathogenesis of such neurodegenerative diseases as HIV
encephalopathy, AD, PD, and ALS (Glass et al., 2010; Valcour
et al., 2011). Microglial activation followed by astrocytic acti-
vation is the earliest pathologic feature in the pre-symptomatic
phases of these diseases. Our recent studies have shown that acti-
vatedmicroglia release excess glutamate through Cx32 hemichan-
nels, resulting in excitotoxic neuronal death (Takeuchi et al., 2006,
FIGURE 3 | The vicious spiral of neuroinflammation and
neurodegeneration mediated by gap junctions and hemichannels.
Microglial glutamate release via hemichannels initiates neuronal damage.
Then, waves of death signals are propagated and amplified via glial and
neuronal gap-junction communication. Chemoattractants from damaged cells
induce infiltration by microglia and macrophages. These infiltrating cells
initiate further neuronal damage and enlarge the lesion of neuroinflammation
and neurodegeneration. This vicious spiral of neuroinflammation and
neurodegeneration may be involved in the progression of various neurologic
diseases.
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2008a; Yawata et al., 2008). Furthermore, microglia-derived glu-
tamate and pro-inflammatory cytokines induce dysfunction of
gap junctions and hemichannels in astrocytes (Kielian, 2008),
thereby potentially disrupting CNS homeostasis. On the other
hand, reactive astrocytes neighboring amyloid β (Aβ) plaques
in the brains of AD patients expressed elevated levels of Cx43
and Cx30 (Koulakoff et al., 2012). Aβ peptide induces the
release of glutamate and ATP via uncoupled hemichannels in
microglia and astrocytes, leading to neuronal death (Orellana
et al., 2011). Corroborating this observation, blockade of gap
junctions/hemichannels improved memory impairment in a
mouse model of AD (Takeuchi et al., 2011). Recent studies also
revealed that astrocytic gap junctions/hemichannels are involved
in the disease progression of HIV encephalopathy (Eugenin and
Berman, 2013; Orellana et al., 2014). PD animal models (MTPT-
treated mice and rotenone-treated rats) exhibited upregulation of
astrocytic Cx43 expression in affected areas (Rufer et al., 1996;
Kawasaki et al., 2009), and a gap junction/hemichannel blocker
ameliorated the disease symptoms of a PD mouse model (Suzuki
et al., 2014). A recent report revealed that α-synuclein directly
binds Cx32, and that overexpression of α-synuclein suppresses
the activity of Cx32 in the SH-SY5Y dopaminergic neuroblas-
toma cell line (Sung et al., 2007). Other studies have shown that
microglia and astrocytes are determinants of disease progression
in ALS (the non-autonomous neuronal death hypothesis) (Boillee
et al., 2006; Yamanaka et al., 2008). Activation of microglia and
astrocytes is associated with elevated expression of gap junctions
and hemichannels (Cui et al., 2014). In fact, treatment with a gap
junction/hemichannel blocker ameliorated disease progression in
a mouse model of ALS (Takeuchi et al., 2011). Juvenile neu-
ronal ceroid lipofuscinosis (JNCL) also shows the activation of
microglia and astrocytes preceding neuronal loss (Pontikis et al.,
2005; Xiong and Kielian, 2013), and treatment with a gap junc-
tion/hemichannel blocker attenuated the disease symptoms of a
JNCL mouse model (Burkovetskaya et al., 2014). Few reports,
however, have focused on the expression profiles and functions
of connexins in these diseases. Further studies are needed to elu-
cidate the precise role of glial connexins in the pathogenesis of
these diseases.
CONCLUSIONS
A growing body of evidence has demonstrated the pathologic
roles of gap junctions and hemichannels in various neurologic
diseases. For example, dysfunction and dysregulation of gap
junctions and hemichannels in glial cells contribute to neuroin-
flammation in the CNS, which results in neuronal damage (a
situation in which glial cells are “bad neighbors” of neurons)
(Block et al., 2007). Despite recent progress in elucidating the
pathological roles of gap junctions and hemichannels, many chal-
lenges remain, due in part to technical limitations. For instance,
few high-quality antibodies against each connexin are available
for immunostaining and immunoblotting. Moreover, reagents
that are commonly used to block connexin channels are not
specific for those channels. In fact, connexin channel blockers
such as glycyrrhetinic acid, its derivative carbenoxolone, niflu-
mic acid, and octanol also block pannexin channels. Although the
most specific gap junction and hemichannel blockers currently
available are mimetic peptides with sequences very similar to
that of the extracellular loop of connexins, recent studies showed
that mimetic peptides specific for Cx32 (32gap 24 and 32gap
27), Cx43 (43gap 27), or Panx1 (10panx1) non-specifically block
both connexins and pannexins (Wang et al., 2007). Although
aptamers and siRNA may be used as blockers for specific con-
nexins (Knieps et al., 2007; Xu et al., 2014), they still have a
problem of the blood–brain barrier penetration. The heterogene-
ity of gap-junction and hemichannel configurations (Figure 2)
and the ability of various connexins to compensate for the loss
of other isoforms (e.g., in connexin-knockout studies) also com-
plicate analysis of this system. Although EGFP-tagged connexins
have facilitated live-cell imaging, tagging and/or overexpression
of connexins in cultured cells often produce abnormally large
gap-junction plaques (Lopez et al., 2001; Gaietta et al., 2002;
Hunter et al., 2003). Moreover, tagging the amino-termini of con-
nexins results in non-functional channels, whereas tagging the
carboxyl-termini alters the properties of the channels (Bukauskas
et al., 2000; Contreras et al., 2003). Therefore, future investiga-
tions should attempt to elucidate the spatiotemporal expression
profiles of connexin isoforms under pathological conditions in
the CNS; this work will require development of specific block-
ers and tracers for each connexin isoform, hemichannel, and gap
junction. Understanding the precise pathologic roles of gap junc-
tions and hemichannels may lead to new therapeutic strategies
against multiple chronic neurodegenerative diseases.
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